Company Overview - enGene Holdings Inc. (NASDAQ:ENGN) is focused on developing non-viral gene therapies for mucosal diseases, particularly in the bladder cancer treatment sector [4] - The company is headquartered in Saint-Laurent, Quebec, and was founded in 1999 [4] Clinical Development - enGene is advancing its lead candidate, detalimogene voraplasmid, into late-stage development for high-risk non-muscle invasive bladder cancer (NMIBC) [3] - A pivotal study is currently underway, with a key data update expected in the second half of 2026 [2] Financial Position - On January 21, enGene expanded its debt facility with Hercules Capital to up to $125 million, which includes $25 million immediately available for refinancing existing debt [3] - The additional financing of up to $100 million is tied to clinical, regulatory, and commercial milestones, enhancing the company's financial flexibility as it transitions to a potential commercial-stage entity [3] Investment Potential - enGene is viewed as a high-risk, high-reward investment opportunity due to its innovative approach and the potential for significant upside in the oncology market [4] - The company's strengthened liquidity and upcoming pivotal data position it favorably within a competitive landscape [4]
Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)